Abstract: Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (PSA), as a marker for the presence or absence of and/or activity of prostate cancer.

Abstract: Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers.

Abstract: A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H64 and/or P98 allele of galectin-3 from a patient's serum sample, and predicting that the patient or population has the propensity to develop cancer based on the presence of the allele. A method of providing prophylactic cancer treatment, by detecting the presence of an H64 and/or P98 allele of galectin-3 from a patient's serum sample, predicting that the patient has the propensity to develop cancer based on the presence of the allele, and recommending and providing prophylactic treatment to the patient to reduce their risk of cancer. A prophylactic anticancer treatment and method of preventing onset or further proliferation of cancer.

Abstract: A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H64 and/or P98 allele of galectin-3 from a patient's serum sample, and predicting that the patient or population has the propensity to develop cancer based on the presence of the allele. A method of providing prophylactic cancer treatment, by detecting the presence of an H64 and/or P98 allele of galectin-3 from a patient's serum sample, predicting that the patient has the propensity to develop cancer based on the presence of the allele, and recommending and providing prophylactic treatment to the patient to reduce their risk of cancer. A prophylactic anticancer treatment and method of preventing onset or further proliferation of cancer.

Abstract: Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers.

Abstract: A method for the treatment of cancer in mammals. A subject afflicted with cancer receives by oral administration a pH modified citrus pectin which inhibits metastasis of primary tumors.

Abstract: A method for the treatment of cancer in mammals. A subject afflicted with cancer receives by oral administration a pH modified citrus pectin which inhibits metastasis of primary tumors.

Abstract: Disclosed are novel polypeptides possessing part or all of the amino acid sequence or primary structural conformation and one or more of the biological properties of certain galactoside-binding-proteins with apparent molecular weights of 34,000 and 31,000. Genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequences of amino acid residues of L-34-gal-lectin and L-31-gal-lectin are incorporated into vectors used to transform a host cell in culture. Also provided are antibodies against L-34-gal-lectin and L-31-gal-lectin and a method for inhibiting mammalian cell metastasis by treating mammalian cells in a living host with antibodies against L-34-gal-lectin or L-31-gal-lectin. A method of determining the metastatic potential of mammalian cells is also provided by which cells in vitro are contacted with antibodies against L-34-gal-lectin or L-31-gal-lectin which are labeled with a detectable probe.

Abstract: Methods and compositions useful in the detection of human cancer cells and malignant tumors are provided. Certain human autocrine motility factor receptors or proteins (gp78-hAMFR) have been identified which are useful in the detection of human cancer cells and malignant tumors. Methods and assay kits for the detection of human cancer, human cancer cells, and tumors, are provided wherein antibodies or nucleotide hybridized probes are used to determine gp78-hAMFR expression. These methods and assays readily distinguish between non-malignant and malignant cancer cells and tumors and can be used to gauge metastatic potential.

Abstract: Methods and compositions useful in the detection of human cancer cells and malignant tumors are provided. Certain human autocrine motility factor receptors or proteins (gp78-hAMFR) have been identified which are useful in the detection of human cancer cells and malignant tumors. Methods and assay kits for the detection of human cancer, human cancer cells, and tumors, are provided wherein antibodies or other probes are used which recognize gp78-hAMFR expression. These methods and assay readily distinguish between non-malignant and malignant cancer cells and tumors and can be used to gauge metastatic potential.

Abstract: Methods and compositions useful in the screening of human bladder cancer cells and malignant tumors are provided. Certain human autocrine motility factor receptors or proteins (gp78-hAMFR) have been identified which are useful in the screening of human bladder cancer cells and malignant tumors. Methods and assay kits for the screening of human bladder cancer, human cancer cells, and tumors, are provided wherein antibodies or other probes are used which recognize gp78-hAMFR expression. These methods and assays readily distinguish between non-malignant and malignant cancer cells and tumors and can be used to gauge metastatic potential.